Name of listed company:	Chugai Pharmaceutical Co., Ltd.
Code number:	4519 (1st Section of Tokyo Stock Exchange)
Head office:	1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO:	Tatsuro Kosaka
Inquiries to:	Masahiko Uchida, General Manager,
	Corporate Communications Dept.
	Tel: +81-(0)3-3273-0881

## Favorable Ruling in Second Patent Infringement Lawsuit Relating to Chugai's Hemlibra

TOKYO, October 3, 2019 -- <u>Chugai Pharmaceutical Co., Ltd.</u> announces today that a ruling in favor of Chugai has been rendered in the second lawsuit relating to Chugai's Hemlibra<sup>®</sup> at the Intellectual Property High Court as follows.

- 1. History Service of Complaint May 10, 2018 Judgement October 3, 2019
- 2. Reasons and Background of the Action

In the original trial, it was alleged by Baxalta that Chugai's Hemlibra (generic name: emicizumab) for treatment of hemophilia A, infringed Baxalta's patent (patent number 4313531) and thus it filed for an injunction in April 2016 against manufacture, usage, transfer, exportation, and offer of any transfer regarding Hemlibra, and disposal of stock. With regard to this action, the Tokyo District Court rendered a decision in favor of Chugai's claim in March 2018. Given this ruling, Baxalta appealed to the Intellectual Property High Court and a decision in favor of Chugai's claim was rendered by the High Court.

3. Party Who Filed the Appeal

i.	Name:	Baxalta Incorporated
		Baxalta GmbH
ii.	Address:	1200 Lakeside Drive Bannockburn, IL 60015, USA
		Zählerweg 4, 6300 Zug, Switzerland

## 4. Contents of the Ruling

- i. Appeal shall be dismissed.
- ii. Court costs shall be borne by Baxalta.

## 5. Prospects

No changes are expected in Chugai's financial prospects.

Trademarks used or mentioned in this release are protected by law.